Opko Health Inc. (NASDAQ:OPK) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 71,681,862 shares, a drop of 1.7% from the October 31st total of 72,919,728 shares. Based on an average trading volume of 4,773,590 shares, the short-interest ratio is presently 15.0 days. Approximately 21.4% of the shares of the company are sold short.
Shares of Opko Health (NASDAQ:OPK) opened at 10.62 on Tuesday. The firm’s market cap is $5.92 billion. The firm has a 50-day moving average price of $9.76 and a 200-day moving average price of $9.88. Opko Health has a 12-month low of $7.12 and a 12-month high of $11.85.
Opko Health (NASDAQ:OPK) last announced its earnings results on Monday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.03). Opko Health had a negative return on equity of 0.49% and a negative net margin of 0.81%. The company had revenue of $298 million for the quarter, compared to analyst estimates of $322 million. During the same period in the prior year, the company posted $0.25 EPS. Opko Health’s quarterly revenue was up 108.4% on a year-over-year basis. On average, equities research analysts expect that Opko Health will post ($0.08) earnings per share for the current fiscal year.
In other Opko Health news, CEO Phillip Md Et Al Frost bought 23,100 shares of the stock in a transaction dated Tuesday, November 8th. The shares were acquired at an average cost of $9.22 per share, for a total transaction of $212,982.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $28,295,728.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 40.74% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Whalerock Point Partners LLC purchased a new stake in Opko Health during the third quarter valued at about $2,100,000. Piedmont Investment Advisors LLC purchased a new stake in Opko Health during the third quarter valued at about $622,000. Price T Rowe Associates Inc. MD raised its stake in Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock valued at $10,038,000 after buying an additional 28,700 shares in the last quarter. Finally, LPL Financial LLC raised its stake in Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock valued at $142,000 after buying an additional 504 shares in the last quarter. 22.27% of the stock is currently owned by institutional investors.
OPK has been the topic of a number of analyst reports. JPMorgan Chase & Co. set a $14.00 price objective on shares of Opko Health and gave the company a “buy” rating in a research report on Tuesday, August 9th. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Tuesday, October 25th. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Opko Health in a research report on Monday, October 10th. Jefferies Group reiterated a “hold” rating and issued a $10.00 price objective on shares of Opko Health in a research report on Monday, October 10th. Finally, TheStreet lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $13.17.
About Opko Health